All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On September 21, 2020, a Biologics Licence Application (BLA) was submitted to the U.S. Food and Drug Administration (FDA) for loncastuximab tesirine for the treatment of patients with relapsed or refractory (R/R) diffuse large B cell lymphoma (DLBCL).1
Loncastuximab tesirine is a novel CD19 targeted antibody–drug conjugate, currently being evaluated in clinical trials for patients with DLBCL and mantle cell lymphoma. The BLA submission is based on data from the single-arm multicenter, open-label, phase II LOTIS 2 trial (NCT03589469) evaluating the safety and efficacy of loncastuxmab tesirine in 145 patients with R/R DLBCL who have received ≥ 2 prior lines of systemic therapy. The data, presented at the 25th congress of the European Hematology Association (EHA) in June 2020, showed an overall response rate of 48.3%, complete response rate of 24.1%, and a manageable tolerability profile for patients treated with loncastuximab tesirine (for an overview of the trial data, see an interview with the EHA congress presenter on the Lymphoma Hub).
If approved, loncastuximab tesirine could help to address an unmet clinical need for patients with DLBCL who have not responded to prior chemotherapies or relapsed from stem cell transplant.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox